Cydan Development Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cydan Development Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12388
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cydan Development Inc (Cydan) is an orphan drug accelerator dedicated to advancing therapies for rare genetic diseases. The company identifies assets with biology and proof-of-concept data in vivo models from academic circles, industry, and other sources. It offers various technology platforms including protein, peptide, nucleic acid, antibody, and AAV gene therapy. Cydan created Imara to develop IMR-687, for the treatment sickle cell disease; and Vtesse which is developing drugs for Niemann-Pick Disease Type C (NPC) and other rare, severe diseases. The company collaborates with patient foundations, academic centres, and biopharmaceutical companies to support drug development. Cydan is headquartered in Cambridge, Massachusetts, the US.

Cydan Development Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cydan Development Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cydan Development Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Cydan Raises USD34 Million in Venture Financing 10
Cydan II (Cydan Development) Raises USD10.66 Million in Venture Financing 12
Cydan Development Raises USD31 Million in Series A Financing 13
Cydan Raises US$26 Million In Venture Financing 14
Equity Offering 16
Vtesse Spin Out from Cydan Development 16
Cydan Development Inc – Key Competitors 17
Cydan Development Inc – Key Employees 18
Cydan Development Inc – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Corporate Communications 20
Apr 09, 2018: Cydan Appoints Chief Business Officer 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Cydan Development Inc, Pharmaceuticals & Healthcare, Key Facts 2
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cydan Development Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cydan Development Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cydan Raises USD34 Million in Venture Financing 10
Cydan II (Cydan Development) Raises USD10.66 Million in Venture Financing 12
Cydan Development Raises USD31 Million in Series A Financing 13
Cydan Raises US$26 Million In Venture Financing 14
Vtesse Spin Out from Cydan Development 16
Cydan Development Inc, Key Competitors 17
Cydan Development Inc, Key Employees 18
Cydan Development Inc, Subsidiaries 19

List of Figures
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Cydan Development Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Constellation Pharmaceuticals Inc (CNST):企業の財務・戦略的SWOT分析
    Constellation Pharmaceuticals Inc (CNST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Seres Therapeutics Inc (MCRB):企業の財務・戦略的SWOT分析
    Summary Seres Therapeutics Inc (Seres), is a microbiome therapeutics platform company that develops a novel class of biological drugs. The company creates a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. The company’ …
  • Hollysys Automation Technologies Ltd:企業の戦略・SWOT・財務分析
    Hollysys Automation Technologies Ltd - Strategy, SWOT and Corporate Finance Report Summary Hollysys Automation Technologies Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Gadeta BV:製薬・医療:M&Aディール及び事業提携情報
    Summary Gadeta BV (Gadeta) is a biotechnology company, which focuses on the research and development of cellular immunotherapies for the elimination of cancer. The company’s technology platform combines alpha beta T cells engineered to express defined Gamma Delta T cell receptors (TEGs) that demonst …
  • Thundelarra Ltd (THX):企業の財務・戦略的SWOT分析
    Summary Thundelarra Ltd (Thundelarra) is a mining and mineral exploration company. The company acquires, explores and develops lead, zinc, silver, nickel, graphite, copper, gold and uranium prospects in Western Australia and the Northern Territory. Its projects include Red Bore Copper-Gold Project, …
  • Verso Corporation:企業の戦略・SWOT・財務情報
    Verso Corporation - Strategy, SWOT and Corporate Finance Report Summary Verso Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Singapore Press Holdings Limited:企業の戦略・SWOT・財務分析
    Singapore Press Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Singapore Press Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Nippon Kayaku Co., Ltd.:戦略・SWOT・企業財務分析
    Nippon Kayaku Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nippon Kayaku Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Jubilee Life Insurance Company Limited:企業の戦略・SWOT・財務情報
    Jubilee Life Insurance Company Limited - Strategy, SWOT and Corporate Finance Report Summary Jubilee Life Insurance Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Flexion Therapeutics Inc (FLXN)-製薬・医療分野:企業M&A・提携分析
    Summary Flexion Therapeutics Inc (Flexion) is a pharmaceutical company that develops and commercializes pain therapies. The company's products comprise FX006, FX007, and FX005. Its FX005 is a p38 mitogen-activated protein, kinase inhibitor that contains both analgesic and anti-inflammatory propertie …
  • Central Garden & Pet Co (CENT):企業の財務・戦略的SWOT分析
    Central Garden & Pet Co (CENT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Newmont Mining Corporation:企業のM&A・事業提携・投資動向
    Newmont Mining Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Newmont Mining Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Akers Biosciences Inc (AKER):製薬・医療:M&Aディール及び事業提携情報
    Summary Akers Biosciences Inc (ABI) is a medical device company that develops, manufactures and supplies point-of-care screening and testing products. The company provides clinical diagnostics, safety diagnostics, and wellness products. Its products include BreathScan alcohol detectors, CHUBE, METRO …
  • Standard Chem & Pharm Co Ltd:企業の戦略・SWOT・財務情報
    Standard Chem & Pharm Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Standard Chem & Pharm Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • VidaCaixa, S.A.U. de Seguros y Reaseguros:企業の戦略・SWOT・財務情報
    VidaCaixa, S.A.U. de Seguros y Reaseguros - Strategy, SWOT and Corporate Finance Report Summary VidaCaixa, S.A.U. de Seguros y Reaseguros - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Fujifilm SonoSite Inc-医療機器分野:企業M&A・提携分析
    Summary Fujifilm SonoSite Inc (Fujifilm SonoSite), a subsidiary of Fujifilm Holdings Corp, is a medical device company. It designs and develops ultrasound systems for use in a variety of medical specialties including anesthesiology, cardiology, critical care, endocrinology, orthopedic surgery, radio …
  • Cascade Metrix LLC:製品パイプライン分析
    Summary Cascade Metrix LLC (CMI) is a medical technology company that commercializes an automated POC blood analyzer for critical care. The company provides product portfolio such as novel micro-volume IV extension kits; and automated glucose monitoring systems, among others. It also provides a revo …
  • Allianz Global Assistance SAS:企業の戦略・SWOT・財務分析
    Allianz Global Assistance SAS - Strategy, SWOT and Corporate Finance Report Summary Allianz Global Assistance SAS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Aspen Insurance Holdings Limited:戦略・SWOT・企業財務分析
    Aspen Insurance Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Aspen Insurance Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • U.S. Army Institute of Surgical Research:医療機器:M&Aディール及び事業提携情報
    Summary U.S. Army Institute of Surgical Research (USAISR), a subsidiary of U.S. Army, is a medical research center that offers solutions for burn, trauma, and combat casualty care from time of injury to rehabilitation. The center conducts research in the areas of dental and trauma research detachmen …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆